**Pharmaceutical Industry:** 60%
**Food and Beverages:** 25%
**Chemical Products:** 15%

**TOP 3 Markets:**
**South Korea:** 50%
**China:** 20%
**Japan:** 15%

Dong-A Socio Holdings Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, which is attributed to its strong position in the healthcare sector. The food and beverage industry as well as chemical products also contribute significantly to the revenue.

Geographically, South Korea is the largest market for the company, followed by China and Japan. These markets are crucial for the growth and stability of the company as they exhibit high demand for Dong-A Socio Holdings' products.

**Production Sites:** South Korea, Vietnam

Dong-A Socio Holdings Co., Ltd. produces the majority of its products in South Korea, where the company's headquarters are also located. Additionally, the company has production facilities in Vietnam to better serve the demand in the Asian markets.

This geographical distribution enables Dong-A Socio Holdings to optimize production costs and shorten delivery times for its customers in the region.

**Current Growth Strategy:** Diversification and International Expansion (2026)

Dong-A Socio Holdings Co., Ltd. is pursuing a strategy of diversification and international expansion to secure future growth. In recent years, the company has increased its investment in research and development to expand its product range and offer innovative solutions in the pharmaceutical sector.

Another focus is on tapping into new markets outside of Korea, particularly in Southeast Asia and Europe. This geographical expansion is intended to be supported by strategic partnerships and joint ventures to leverage local market knowledge and overcome market entry barriers.

Additionally, the company is focusing on sustainable practices and the development of environmentally friendly products to meet the growing demands for sustainability and to tap into new customer segments.

**Main raw materials:** Pharmaceutical active ingredients, chemicals, packaging materials

**Countries of origin:** China, Germany, USA, India

Dong-A Socio Holdings Co., Ltd., a leading company in the pharmaceutical industry, imports a variety of raw materials necessary for the production of their products. The most important imported materials include pharmaceutical active ingredients and special chemicals used in the production of medications.

China and India are significant suppliers of pharmaceutical active ingredients due to their strong production capacity and cost-effective manufacturing processes. Germany and the USA supply high-quality chemicals and packaging materials that meet the high quality standards of the pharmaceutical industry.

This diversification of sources helps Dong-A Socio Holdings ensure a secure supply while benefiting from the respective strengths of the supplying countries.

**Market share:** 12% (estimated, 2026)
**R&D expenses:** 8% of revenue (2025)
**Brand awareness:** High in South Korea (2026)

Dong-A Socio Holdings Co., Ltd. has a significant competitive advantage, especially in its home market of South Korea, where it enjoys high brand awareness. The company continuously invests in research and development, accounting for about 8% of its revenue. These investments enable it to develop innovative products and stand out from the competition.

Another advantage is the diversification of its product portfolio, which includes both pharmaceutical and non-pharmaceutical products. This reduces dependence on individual market segments and stabilizes revenue. The estimated market share of 12% indicates that the company holds a strong position in the industry, despite operating in a competitive environment.

In summary, Dong-A Socio Holdings possesses a solid competitive advantage through its innovation, strong brand presence, and diversified product portfolio.

**Institutional Investor Share:** Estimate: 45% (2026)

**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in Dong-A Socio Holdings Co., Ltd. is estimated to be around 45%. This figure is based on the typical pattern of holdings in large South Korean companies where institutional investors play a significant role.

Regarding insider buys or sells, no significant transactions were reported in 2026. This suggests that there are no significant changes in the management's or major shareholders' confidence in the company's future development.

**Market share of Dong-A Socio Holdings Co., Ltd.:** Estimate: 5-7% (2026)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 15%
2. **Celltrion:** 12%
3. **Hanmi Pharmaceutical:** 10%
4. **LG Chem (Pharma division):** 8%
5. **Dong-A Socio Holdings Co., Ltd.:** 5-7%
6. **Yuhan Corporation:** 5%
7. **Daewoong Pharmaceutical:** 4%
8. **GC Pharma:** 3%
9. **SK Biopharmaceuticals:** 3%
10. **Kolon Life Science:** 2%

Dong-A Socio Holdings Co., Ltd. has a moderate market share compared to the leading companies in the industry. The company's moat mainly lies in its established brand presence and diversified product portfolio, which includes both pharmaceutical products and healthcare services.

In comparison to its competitors, Dong-A Socio Holdings has a less pronounced moat, as companies like Samsung Biologics and Celltrion have a significant competitive advantage through their strong research and development efforts and international partnerships. These companies heavily invest in innovative technologies and have a broader global reach, strengthening their market position.

Dong-A Socio Holdings could enhance its moat by increasing investments in research and development and by forming strategic partnerships to boost its competitiveness.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Research and Development Ratio:** 12% of revenue (2025)

Dong-A Socio Holdings Co., Ltd. achieved solid revenue growth of 8.5% in 2025, attributed to a strong market position and successful product lines. The 10.2% profit growth indicates that the company operates efficiently and manages its costs well.

Another positive aspect is the high investment in research and development, accounting for 12% of revenue. This suggests that the company is investing in the future and focusing on innovation to remain competitive.

Additionally, the company has a diversified product range and a strong presence in various international markets, reducing risk and increasing the potential for further growth. Analysts view the company's strategic direction and innovation capabilities as positive signals for long-term investments.

**Dividend yield:** 1.8% (2025)
**Dividend history:** Consistent payout over the last 5 years

Dong-A Socio Holdings Co., Ltd. has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield was approximately 1.8% in 2025, which can be considered moderate compared to other companies in the industry.

The consistent payout over the past five years indicates that the company is committed to continuously returning capital to its shareholders. This suggests a stable financial position and a sustainable business model. Analysts may expect this practice to continue as long as there are no significant negative changes in financial performance or market conditions.